

## **A Novel Barrier Device and Method for Protection against Airborne Pathogens During Endotracheal Intubation**

### **Running Head: A Novel Barrier Device for Endotracheal Intubation.**

Julio M. Alonso M.D.<sup>1,2</sup>, Jeffrey Lipman M.D., Ph.D.<sup>2,3,4</sup>, Kiran Shekar M.D., Ph.D.<sup>1,5</sup>

<sup>1</sup> Adult Intensive Care Services and Critical Care Research Group, The Prince Charles Hospital, Brisbane, Queensland, Australia

<sup>2</sup> The University of Queensland, Brisbane. Queensland, Australia

<sup>3</sup> Jamieson Trauma Institute and Intensive Care Services, Royal Brisbane and Women's Hospital, Brisbane

<sup>4</sup> Nimes University Hospital, University of Montpellier, Nimes, France

<sup>5</sup> Queensland University of Technology, Brisbane; University of Queensland, Brisbane; and Bond University, Gold Coast. Queensland, Australia

#### **Address correspondence to:**

Dr Julio M Alonso.

Adult Intensive Care Services. The Prince Charles Hospital.

Rode Road. Chermside West. QLD 4032. Australia

Phone: +61 434 940 786

E-mail: [j.alonsobabarro@uq.edu.au](mailto:j.alonsobabarro@uq.edu.au)

1 **ABSTRACT**

2 **Background**

3 The risk of SARS-CoV-2 transmission to healthcare workers increases during aerosol-  
4 generating procedures such as endotracheal intubation.

5 **Objectives**

6 We tested the effectiveness of a novel barrier mouthpiece in reducing clinician exposure  
7 to aerosols and droplets during endotracheal intubation.

8 **Design**

9 A prospective case control study was carried out, with a single operator performing  
10 eight simulated intubations with and without the device on two different high-fidelity  
11 manikin models which produced aerosols and droplets.

12 **Setting**

13 The study was performed during June 2020, at the Clinical Skills Development Service,  
14 Brisbane, Australia.

15 **Interventions**

16 Simulated scenarios included 1) intubation during cardiopulmonary resuscitation 2)  
17 intubation while pre-oxygenating via high flow nasal cannula. Photographic images  
18 were obtained during each intubation and digitally analyzed using ImageJ v2.1.0/1.53c.

19 **Patients**

20 Not applicable.

21 **Main outcome measures**

22 Aerosol and droplets were quantified using pixel counts. Overall results were expressed  
23 as means ( $\pm$  SD), with comparisons between groups made using a two-tailed Student's  
24 T-test under the assumption of unequal variances. A P value of  $\leq 0.05$  was considered  
25 as statistically significant.

26 **Results**

27 First pass intubation was achieved in all scenarios, with and without the barrier device.  
28 Pixel counts demonstrated significant overall reduction in aerosol and droplet exposure  
29 when the barrier device was used during intubation [Mean (SD) count:509 (860) vs

30 10169 (11600); P=0.014]. The highest exposure risk to airborne particles was observed  
31 during simulated induction, prior to laryngoscopy and intubation.

### 32 **Conclusions**

33 The novel barrier device was effective in reducing environmental exposure to aerosols  
34 and droplets during intubation without negatively affecting first pass intubation. The  
35 highest risk of exposure to airborne particles was during induction, before intubation  
36 takes place. Clinical trials are indicated to further test the feasibility and efficacy of this  
37 device.

### 38 **Trial registration**

39 Not applicable.

40 **Keywords:** Endotracheal intubation, SARS-CoV-2, COVID-19, Prevention, Safety

41

## 42 **KEY POINTS**

- 43       • This prospective, preclinical study represents a pilot trial of a novel barrier  
44       mouthpiece for reducing clinician exposure to aerosols and droplets during  
45       endotracheal intubation.
- 46       • In eight simulated intubations with and without the barrier mouthpiece, the  
47       device proved effective in reducing environmental exposure to aerosols and  
48       droplets (measured in pixels) during intubation, without negatively affecting  
49       first pass intubation.
- 50       • The novel barrier mouthpiece represents a possible solution for reducing the risk  
51       of respiratory pathogen transmission during endotracheal intubation without  
52       hampering the procedure itself, although larger preclinical and clinical trials are  
53       necessary.

54

## 55 **Background**

56 From December 2019 - when the first cases of novel SARS-CoV-2 infection were  
57 described<sup>1</sup> - to May 2020 alone, over 152,888 healthcare workers had already been  
58 infected by the virus<sup>2</sup>, accounting for up to 17.2% of hospital admissions (including  
59 healthcare workers' households) for COVID-19<sup>3</sup>. Subsequent studies have confirmed  
60 that COVID-19 is an airborne disease<sup>4,5</sup>, pointing to an increased risk of transmission  
61 during aerosol generating procedures such as cardiopulmonary resuscitation (CPR) or  
62 endotracheal intubation (ETI), a procedure performed in up to 20% of severely ill  
63 patients with COVID-19<sup>6</sup>. Worldwide shortages of personal protective equipment  
64 (PPE), especially in under-resourced environments and developing countries, have led  
65 to increased concerns about inequalities regarding access to necessary protection for  
66 healthcare workers during this and other procedures<sup>7</sup>. On the other hand, PPE itself  
67 may not be the panacea for eliminating the risk of SARS-CoV-2 transmission during  
68 aerosol-generating procedures. In their observational cohort, Boghdadly *et. al* describe  
69 around 10% incidence of COVID-19 symptoms in healthcare workers involved in the  
70 ETI of patients with the disease, despite the majority wearing adequate PPE as defined  
71 by the World Health Organization<sup>8</sup>.

72 To provide an extra level of protection for frontline workers during intubation of  
73 COVID-19 patients, recent publications have documented the rise of initiatives such as  
74 'intubation teams' comprising of experienced anesthesiologists<sup>9,10</sup>, *ad hoc* intubation  
75 protocols<sup>11</sup>, dedicated negative pressure rooms<sup>12</sup>, and protective barrier enclosures, of  
76 which the best-known example is the 'aerosol box', designed by Dr. Hsien Yung Lai, a  
77 Taiwanese anesthesiologist<sup>13</sup>. Further versions of the aerosol box, including the  
78 addition of a negative-pressure chamber, have also been developed<sup>14</sup>. However, despite  
79 initial traction and widespread use in clinical practice, subsequent studies in simulation  
80 models and clinical practice<sup>15</sup> have provided evidence that these devices could pose a  
81 risk for patient safety, due to increased intubation times<sup>16</sup>. In addition, these devices  
82 may hamper access to the airway, and may paradoxically increase healthcare worker  
83 infection rates because of increased exposure to aerosols during removal of the barrier  
84 enclosure<sup>17</sup>. These findings led to the FDA withdrawing its Emergency Use Approval  
85 for protective barrier enclosures in August 2020.

86 To the best of our knowledge, no current alternative to protective barrier enclosures  
87 exists that offers an extra layer of protection for physicians and their teams during  
88 intubation of patients with COVID-19 or other respiratory infections, while ensuring  
89 correct access to the airway and guaranteeing the feasibility of the procedure. Therefore,  
90 we designed a barrier mouthpiece – the Airway Shield<sup>TM</sup> - which restricts the spread of  
91 aerosols and droplets during the endotracheal intubation procedure by covering the  
92 patient’s mouth, while facilitating intubation itself via a cannula that is inserted between  
93 the patient’s tongue and the palate, allowing the introduction of the laryngoscope’s  
94 blade and the endotracheal tube, and guiding the endotracheal tube towards the larynx.

95 The objective of our study is to evaluate the effectiveness of this novel device regarding  
96 the reduction of aerosols and droplets liberated during ETI, compared to conventional  
97 intubation without the device. Secondary objectives include assessing the feasibility of  
98 endotracheal intubation with the device, measured as first pass intubation, and  
99 quantifying the risk of aerosol and droplet spread in different moments of the procedure.

100

## 101 **Methods**

102 The study was carried out at the Clinical Skills Development Service (CSDS) in  
103 Brisbane, Australia, during June 2020. This institution provides simulation-based  
104 training for healthcare professionals from the Queensland Health workforce and offers a  
105 large range of devices and venues for preclinical research.

106 The study was designed to evaluate Airway Shield's efficacy in reducing droplet  
107 (airborne particles > 5µm in diameter) and aerosol (airborne particles < 5µm in  
108 diameter)<sup>18</sup> exposure when performing ETI during CPR and during controlled ETI  
109 while maintaining oxygenation with High Flow Nasal Canula (HFNC), with and  
110 without Airway Shield. High-fidelity simulated ETIs were performed on manikins  
111 capable of producing droplets and aerosols. Imaging software (ImageJ) was used to  
112 measure and compare the spread of droplets and aerosols in the different scenarios.

## 113 **Ethics**

114 Our study was carried out in accordance with the ethical principles set out in the  
115 Declaration of Helsinki. Ethical approval for this study was not required as no animals  
116 or human patients were involved.

## 117 **Device characteristics**

118 The device tested in this study was a 3-D printed prototype, built in medical grade TPU  
119 material with a Shore A hardness durometer scale of 80, specifically chosen to give a  
120 consistency that maintains and recovers its form, while being soft enough to avoid  
121 damage of the mucosa of a patient when introduced through the mouth and placed  
122 between the palate and the tongue (Figures 1, 2 and 3). This novel barrier device has  
123 three main components: A shield, to cover the patient's mouth; a working channel, with  
124 two openings, a proximal one, at the level of the shield, and a distal one at the other end;  
125 and a seal, to cover the proximal opening and restrict aerosol spread while permitting  
126 the insertion of the blade of a laryngoscope and the endotracheal tube through it.  
127 Additionally, two small, sealed openings at both sides of the main proximal opening at  
128 the level of the shield, provide access for catheters for the suction of fluids or aerosols  
129 during ETI (Figures 1 and 2).

## 130 **Technique of intubation with the novel device**

131 Endotracheal intubation with the Airway Shield is performed in 3 steps. First, during  
132 induction, the device is placed: the working channel is introduced into the mouth of the  
133 patient following the palate, until the shield covers the mouth. Second, ETI is  
134 performed: as in a standard ETI, the video-laryngoscope blade is introduced first to  
135 obtain a view of the larynx, followed by the ETT (endotracheal tube), in this case  
136 following the blade through the working channel, towards the larynx. Finally, the  
137 Airway Shield is removed: once the ETT is in place and the ventilator is connected, the  
138 device is peeled away from the midline and removed. (Figure 3 and Additional File 2:  
139 multimedia content).

#### 140 **Manikin preparation**

141 For this study, we designed two different manikin models to produce aerosols and  
142 droplets. To simulate and evaluate the spread of aerosols during the intubation  
143 procedure, a resuscitation manikin (Megacode Kelly, Laerdal) was modified by  
144 connecting a nebulizer (Aerogen Solo, Aerogen) for inhalation to the reservoir bag of a  
145 self-inflating bag connected to the lungs, and powered by a ventilator (Servo U,  
146 Maquet), thus permitting the nebulization of an ultraviolet light-sensitive fluid into the  
147 simulated airway. Continuous airflow (6L/minute) was applied to the nebulizer to  
148 ensure sufficient aerosol visualization. To evaluate the spread of droplets, an atomizer  
149 connected by a long tubing to a syringe containing colored fluid (green dye mixed with  
150 water) was placed at the level of the manikin's oropharynx, pointing towards the mouth  
151 (Additional File 1: Manikin Preparation).

#### 152 **Simulated endotracheal intubation**

153 We tested the device for the environmental exposure of both aerosols and droplets in  
154 two different scenarios – intubation during cardiopulmonary resuscitation (CPR) and  
155 intubation during oxygenation with high flow nasal cannula (HFNC) – and compared  
156 the results with those obtained in the same scenarios during conventional intubation. A  
157 total of eight simulated intubations were performed by a single operator, with first pass  
158 intubation recorded as a dichotomous variable (yes/no). The same sequence of  
159 simulations was followed for the scenarios evaluating the spread of droplets. (Further  
160 documentation on the complete sequence of events is available in Appendix C and D)

161 During the simulations, photographs were taken at a rate of 6 frames per second to  
162 capture data on the spread of aerosols and droplets at three moments of each simulated



163 clinical scenario: just before introduction of the laryngoscope into the manikin's mouth  
164 (corresponding to anesthetic induction); during initial laryngoscopy; and during the  
165 introduction of the endotracheal tube. The spread of aerosols and droplets was  
166 documented by photographs taken from a fixed angle against a dark background. In  
167 order to quantify and compare results, the photograph showing the highest spread of  
168 aerosols and droplets was chosen for each scenario. All photographs measured 1920 x  
169 1280 pixels.

#### 170 **Data analysis**

171 Images from each scenario were selected according to the maximum count of droplets  
172 or aerosols in each setting and were converted from color to black and white in order to  
173 permit digital analysis. A manual polygonal selection of the areas in which aerosols and  
174 droplets were visualized was carried out. Captured data were analyzed with detection  
175 and automatic count of aerosols and droplets using ImageJ v2.1.0/1.53c, an open-source  
176 package for the processing and analysis of scientific images.

177 Aerosol and droplets were quantified using pixel counts. Overall results were expressed  
178 as means ( $\pm$  SD), with the comparison between groups made using a two-tailed  
179 Student's T-test under the assumption of unequal variances. A P value of 0.05 or less  
180 was considered to indicate statistical significance. Statistical analysis of the results was  
181 carried out using R version 4.1.0 (© 2021 The R Foundation for Statistical Computing).

182

183

184 **Results**

185

186 24 images were selected for digital analysis using automatic pixel counts (Figures 4 and  
187 5 and Additional File 3), after previous manual selection of the area in which aerosols  
188 or droplets had been detected. Pixel counts demonstrated significant overall reduction of  
189 aerosols and droplets during ETI in high-fidelity clinical simulations with Airway  
190 Shield compared to intubation without the device (509 (859.96) vs 10168.91  
191 (11600.63);  $P=0.014$ ), as shown in Table 1. When analyzed by subgroups (Table 2),  
192 Airway Shield reduced the spread of aerosols by 12-fold on average ( $P=0.045$ ). The  
193 spread of droplets was reduced by an average of 43-fold, although this result was not  
194 statistically significant.

195 First pass success was achieved in all clinical scenarios, both with and without Airway  
196 Shield. The operator did not describe difficulty while carrying out the procedure in any  
197 of the simulated intubation scenarios.

198 Regarding the risk of aerosol and droplet spread during the different moments of the  
199 endotracheal intubation procedure, highest counts of airborne particles were observed  
200 during simulated induction, before carrying out initial laryngoscopy and intubation  
201 (Figure 6). This difference was maintained in both CPR and HFNC scenarios,  
202 independently of whether Airway Shield was used.

203

204 **Discussion**

205

206 The primary objective of our study was to test Airway Shield’s potential for reducing  
207 the spread of aerosols and droplets during ETI, as compared to intubation without the  
208 device. We simulated clinical scenarios in specifically designed manikin models and  
209 used automatic pixel counts as a surrogate marker of the reduction in spread of droplets  
210 and aerosols generated by patients in real-life settings. Our results showed that this  
211 novel barrier mouthpiece demonstrated significant overall reduction of airborne  
212 particles, while permitting a consistent first pass success rate in all simulated  
213 intubations. These findings confirm Airway Shield’s effectiveness as a barrier device  
214 against aerosols and droplets, while at the same time permitting successful ETI.

215 Our results offer a novel perspective on barrier devices designed to reduce exposure to  
216 airborne particles during intubation. This study is the first to present a specifically  
217 designed mouthpiece which demonstrates effective protection from aerosols and  
218 droplets while permitting successful ETI. The novelty of this device stems from the fact  
219 that it successfully covers the patient’s mouth without impeding first pass intubation.

220 Regarding the risk of aerosol and droplet spread during the different moments of the  
221 endotracheal intubation procedure, our study demonstrated a consistently higher count  
222 of airborne particles during induction in all but one scenario. To our knowledge, this  
223 study is the first to address the risk of exposure to aerosols and droplets at specific  
224 moments of the procedure. Although the number of experiments is too small to permit  
225 statistical comparison, we raise the hypothesis that induction may be the moment of  
226 highest risk for healthcare professionals carrying out the intubation procedure.

227 Our study has four main limitations. First, it is a preclinical study in manikin models,  
228 using pixel counts as surrogate markers for the aerosols and droplets generated by  
229 patients during ETI. Second, the possibility of small variations in the flow of aerosols  
230 and droplets produced by the manikins cannot be completely eliminated. Third, the  
231 manual polygon selection process may affect reproducibility of the results. Finally, the  
232 number of simulated scenarios is relatively small; however, the variations in aerosol and  
233 droplet spread are large enough to permit statistically significant conclusions.

234 **Conclusions**

235 Our study suggests that Airway Shield, a novel barrier mouthpiece, is effective in  
236 reducing the spread of aerosols and droplets during ETI, while permitting successful  
237 first pass intubation. The results offer a novel perspective on barrier devices and open  
238 the door to the possibility of using a mouthpiece to protect healthcare workers during  
239 ETI, an aerosol generating procedure. Our findings also generate the hypothesis that the  
240 moment of highest risk of exposure to airborne particles is, in fact, during induction,  
241 before the actual intubation takes place.

242 Further research is necessary to confirm these findings, including larger simulation  
243 studies and clinical trials to evaluate safety and efficacy of Airway Shield.

244

245 **Acknowledgements relating to this article:**

246

247 **Assistance with the article:**

248 The authors would like to thank the ‘Clinical Skills Development Service’ in Brisbane  
249 and Clinton Henderson for their contribution setting up the manikins used for the study,  
250 Cambell Smyth for his contribution in the CAD design of the device and the drawings  
251 presented in this article, Joanne Zuo for her contribution with the digital data analysis,  
252 Jose Medrano for his suggestions for the design of the study, and Sergio Lordao and  
253 Michael Minoza for their contribution taking the photos and video.

254

255 **Financial support and sponsorship:** None

256 **Conflicts of interest:** J.M.A. has created the concept and design of the Airway  
257 Shield™ and has filed an international patent for commercial use. J.L. and K.S. have no  
258 conflicts of interest to declare.

259

260 **Presentations:** None

261

262

263 **References**

- 264 1. Ge H, Wang X, Yuan X, et al. The epidemiology and clinical information about  
265 COVID-19. *Eur J Clin Microbiol Infect Dis*. 2020;39(6):1011–9.
- 266 2. Bandyopadhyay S, Baticulon RE, Kadhum M, et al. Infection and mortality of  
267 healthcare workers worldwide from COVID-19: a systematic review. *BMJ Glob*  
268 *Health*. 2020;5(12):e003097.
- 269 3. Shah AS, Wood R, Gribben C, et al. Risk of hospital admission with coronavirus  
270 disease 2019 in healthcare workers and their households: nationwide linkage  
271 cohort study. *BMJ*. 2020;371:m3582
- 272 4. Wilson NM, Marks GB, Eckhardt A, et al. The effect of respiratory activity,  
273 non-invasive respiratory support and facemasks on aerosol generation and its  
274 relevance to COVID-19. *Anaesthesia* [online ahead of print] 30 March 2021;  
275 [https://associationofanaesthetists-](https://associationofanaesthetists-publications.onlinelibrary.wiley.com/doi/10.1111/anae.15475)  
276 [publications.onlinelibrary.wiley.com/doi/10.1111/anae.15475](https://associationofanaesthetists-publications.onlinelibrary.wiley.com/doi/10.1111/anae.15475)
- 277 5. Weissman DN, De Perio MA, Radonovich LJ. COVID-19 and risks posed to  
278 personnel during endotracheal intubation. *JAMA*. 2020;323(20):2027–8.
- 279 6. Halpern NA, Tan KS. United States resource availability for COVID-19. *Critical*  
280 *Care Statistics*. 2020. [https://sccm.org/Blog/March-2020/United-States-Resource-](https://sccm.org/Blog/March-2020/United-States-Resource-Availability-for-COVID-19?_zs=jxpjd1&_zl=w9pb6)  
281 [Availability-for-COVID-19?\\_zs=jxpjd1&\\_zl=w9pb6](https://sccm.org/Blog/March-2020/United-States-Resource-Availability-for-COVID-19?_zs=jxpjd1&_zl=w9pb6). Accessed 27 JUL 2021.
- 282 7. Minayo MC de S, Freire NP. The pandemic exacerbates health inequalities. *Cien*  
283 *Saude Colet*. 2020;25:3555–6.
- 284 8. El-Boghdadly K, Wong DJN, Owen R, et al. Risks to healthcare workers following  
285 tracheal intubation of patients with COVID-19: a prospective international  
286 multicentre cohort study. *Anaesthesia*. 2020;75(11):1437–47.
- 287 9. Cook TM, El-Boghdadly K, McGuire B, McNarry AF, Patel A, Higgs A. Consensus  
288 guidelines for managing the airway in patients with COVID-19: Guidelines from  
289 the Difficult Airway Society, the Association of Anaesthetists the Intensive Care

- 290 Society, the Faculty of Intensive Care Medicine and the Royal College of  
291 Anaesthetists. *Anaesthesia*. 2020;75(6):785–99.
- 292 10. Gandhi A, Sokhi J, Lockie C, Ward PA. Emergency tracheal intubation in patients  
293 with COVID-19: experience from a UK Centre. *Anesthesiology research and*  
294 *practice*. [Serial online] 2020 Dec [Cited 2021 Jul 27]. Available from:  
295 <https://www.hindawi.com/journals/arp/2020/8816729/>
- 296 11. Miller L, Luković E, Wagener G. Guiding airway management and personal  
297 protective equipment for COVID-19 intubation teams. *Br J Anaesth*.  
298 2020;125(3):e288–90.
- 299 12. Matava CT, Kovatsis PG, Summers JL, et al. Pediatric airway management in  
300 Coronavirus disease 2019 patients: consensus guidelines from the society for  
301 pediatric anesthesia’s pediatric difficult intubation collaborative and the Canadian  
302 pediatric anesthesia society. *Anesth Analg* [Online ahead of print] 13 Apr 2020;  
303 <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7173403/>
- 304 13. Malik JS, Jenner C, Ward PA. Maximising application of the aerosol box in  
305 protecting healthcare workers during the COVID-19 pandemic. *Anaesthesia*.  
306 2020;75(7):974.
- 307 14. Gupta V, Sahani A, Mohan B, Wander GS. Negative pressure aerosol containment  
308 box: An innovation to reduce COVID-19 infection risk in healthcare workers. *J*  
309 *Anaesthesiol Clin Pharmacol*. 2020;36(Suppl 1):S144.
- 310 15. Tighe NT, McClain CD, Vlassakova BG, et al. Aerosol barriers in pediatric  
311 anesthesiology: Clinical data supports FDA caution. *Pediatr Anaesth*.  
312 2021;31(4):461–4.
- 313 16. Lim ZJ, Reddy MP, Karalapillai D, Shekar K, Subramaniam A. The impact of an  
314 aerosol box on time to tracheal intubation: systematic review and meta-analysis. *Br*  
315 *J Anaesth*. 2021; 126(3):e122-e125
- 316 17. Begley JL, Lavery KE, Nickson CP, Brewster DJ. The aerosol box for intubation in  
317 coronavirus disease 2019 patients: an in situ simulation crossover study.  
318 *Anaesthesia*. 2020;75(8):1014–21.

319 18. Fennelly KP. Particle sizes of infectious aerosols: implications for infection control.

320 The Lancet Respiratory Medicine. 2020; 8(9): 914-924

321



322 **Table Legends**

323 Table 1: Aerosol and droplet count in high-fidelity clinical simulations of endotracheal  
324 intubation (ETI)

325 Table 2: Overall comparison of aerosol and droplet counts

326

327 **Figure Legends:**

328 Figure 1A: Components of the Airway Shield™ barrier mouthpiece device; Front view.

329 Figure 1B: Components of the Airway Shield™ barrier mouthpiece device; Rear view.

330 Figure 1C: Components of the Airway Shield™ barrier mouthpiece device; Right side  
331 view.

332 Figure 2: Functional position of the Airway Shield™: Working channel allocated  
333 between the tongue and the palate; shield covering the patient's mouth

334 Figure 3A: Endotracheal intubation with the aid of the Airway Shield™: Insertion.

335 Figure 3B: Endotracheal intubation with the aid of the Airway Shield™: Laryngoscopy.

336 Figure 3C: Endotracheal intubation with the aid of the Airway Shield™: Intubation.

337 Figure 4: Simulated induction during ETI and CPR in aerosol manikin model.

338 Figure 5: Simulated induction during ETI with HFNC oxygenation in droplet manikin  
339 models.

340 Figure 6: Risk of aerosol and droplet spread during different moments of the intubation  
341 procedure. Aerosol and droplet counts, in pixels, are depicted in the logarithmic scale.

342

343 **Additional Files**

344 Additional File 1: Manikin Preparation

345 Additional File 2: Multimedia Content

346 Additional File 3: Dataset with all 24 shots from the 8 simulated scenarios during CPR  
347 and HFNC in droplet and aerosol manikin models performed for the study. Figures with  
348 original color photos, black and white photos, and digital pixel counts.

349

Table 1

Aerosol and droplet count in high-fidelity clinical simulations of endotracheal intubation (ETI)

Scenario	Manikin model	With Airway Shield™	Without Airway Shield™
ETI† during CPR - induction	Aerosol	3047	24001
ETI during CPR – initial laryngoscopy	Aerosol	850	7324
ETI during CPR – intubation	Aerosol	655	8694
ETI and oxygenation with HFNC – induction	Aerosol	0	9308
ETI and oxygenation with HFNC – initial laryngoscopy	Aerosol	23	2618
ETI and oxygenation with HFNC – intubation	Aerosol	0	3256
ETI during CPR	Droplet	616	21919

- induction			
ETI during CPR	Droplet	616	7178
– initial laryngoscopy			
ETI during CPR	Droplet	206	583
– intubation			
ETI and oxygenation with HFNC	Droplet	78	37142
– induction			
ETI and oxygenation with HFNC	Droplet	1	2
– initial laryngoscopy			
ETI and oxygenation with HFNC	Droplet	16	2
– intubation			
Mean ( $\pm$ SD)		509	10168.91
		(859.96) *	(11600.63) *

Results are measured in pixels. \*P=0.015. †ETI, endotracheal intubation; CPR, cardiopulmonary resuscitation; HFNC, high-flow nasal prongs; SD, standard deviation.

Table 2

Overall comparison of aerosol and droplet counts

Manikin model	With Airway Shield <sup>TM</sup>	Without Airway Shield <sup>TM</sup>
Aerosol	762.5 (1178.79) *	9200.16 (7765.44) *
Droplet	255.5 (288.45)	11137.67 (15281.02)
Total	509 (859.96) *	10168.91 (11600.63) *

Results are measured in pixels. \*P<0.05.

Figure 1A




Figure 1B





Figure 1C



1. Shield
2. Working channel
3. Seal of the proximal opening of the working channel
4. Distal opening of the working channel
5. Suction ports
6. Line for peel-off removal

Figure 2




Figure 3A



Figure 3B




Figure 3C






Figure 4

Size of the picture is 1920x1280 pixels




1920x1280 pixels; 8-bit; 2.3MB


1920x1280 pixels; 8-bit; 2.3MB



1920x1280 pixels; 8-bit; 2.3MB



1920x1280 pixels; 8-bit; 2.3MB




Result:

	Slice	Count	Total Area	Average Size
①	Scenario 1.1.jpg	1104	24001	21.740
②	Scenario 2.1.jpg	28	3047	108.821

Count = number of areas  
 Total Area = total size of all areas  
 Average Size = average size of each area  
 (Unit of area: PIXEL)

Figure 5

Size of the picture is 1920x1280 pixels



Result:

Slice	Count	Total Area	Average Size
① Scenario 5.1.jpg	1126	21919	19.466
② Scenario 6.1.JPG	87	616	7.080

(Unit of area: PIXEL)

Count = number of areas  
 Total Area = total size of all areas  
 Average Size = average size of each area

Figure 6

